Loading
Sometimes a progression biopsy shows exactly which drug would help, but it is licensed for another cancer and cannot be obtained. A standing pathway would fix that.
Mechanism-matched treatment recommendations frequently fail at the access step. A national pathway modelled on the Dutch DRUP and UK-style access schemes would combine a molecular tumour board decision, company-supplied drug, mandatory outcome registration and payer participation, so that every off-label use generates evidence. This converts scattered compassionate use into a structured cohort study.
Shares Netherlands Cancer Institute (NKI-AvL), Tumour-agnostic (tissue-agnostic) approval, No incentive to repurpose cheap drugs, Real-world evidence.
Shares No incentive to repurpose cheap drugs, Regulatory divergence between regions.
Shares No incentive to repurpose cheap drugs, Regulatory divergence between regions.
Shares Real-world evidence, Regulatory divergence between regions.
Shares Real-world evidence, Regulatory divergence between regions.
Shares No incentive to repurpose cheap drugs, Regulatory divergence between regions.
Shares Real-world evidence, Regulatory divergence between regions.
Shares No incentive to repurpose cheap drugs, Real-world evidence.